Locke, Frederick L. http://orcid.org/0000-0001-9063-6691
Filosto, Simone
Chou, Justin
Vardhanabhuti, Saran
Perbost, Regis
Dreger, Peter
Hill, Brian T.
Lee, Catherine
Zinzani, Pier L.
Kröger, Nicolaus http://orcid.org/0000-0001-5103-9966
López-Guillermo, Armando
Greinix, Hildegard
Zhang, Wangshu
Tiwari, Gayatri
Budka, Justin
Marincola, Francesco M.
To, Christina
Mattie, Mike
Schupp, Marco
Cheng, Paul
Bot, Adrian
Shen, Rhine
Bedognetti, Davide
Miao, Harry
Galon, Jérôme
Article History
Received: 30 March 2023
Accepted: 5 December 2023
First Online: 17 January 2024
Competing interests
: The authors declare the following competing interests: F.L.L. reports a consulting or advisory role for Allogene, Amgen, Bluebird Bio, BMS/Celgene, Calibr, Cellular Biomedicine Group, Cowen, ecoR1, Emerging Therapy Solutions Gerson Lehman Group, GammaDelta Therapeutics, Iovance, Janssen, Kite, a Gilead Company, Legend Biotech, Novartis, Umoja and Wugen; research funding from Allogene, Kite and Novartis; and patents, royalties and other intellectual property in the field of cellular immunotherapy. S.F. reports employment and stock or ownership with Kite, a Gilead Company, and patents, royalties and other intellectual property from Tusk Therapeutics. J.C. reports employment with, leadership role in and travel support from Kyverna and Kite, a Gilead Company; stock or other ownership in Gilead Sciences; and research funding, patents, royalties and other intellectual property from Kite. S.V. reports employment with and research funding from Kite, a Gilead Company; and stock or other ownership in Gilead Sciences. R.P. reports employment and stock or other ownership with Veracyte. P.D. reports a consulting or advisory role for, honoraria from and speakers’ bureau participation for Bristol-Myers Squibb, Gilead Sciences and Novartis. B.T.H reports honoraria from, a consulting or advisory role for, research funding from and travel support from Kite, a Gilead Company. C.L. reports stock in Kadmon; honoraria from CareDX, Jazz, Kadmon and Kite, a Gilead Company; a consulting or advisory role for Fresenius Kabi; and research funding from Incyte. P.L.Z. reports a consultant role for MSD, Eusa Pharma and Novartis; speakers’ bureau participation for Celltrion, Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, Servier, MSD, TG Therapeutics, Takeda, Roche, Eusa Pharma, Kyowa Kirin, Novartis, Incyte, and Beigene; and advisory board participation for Secura Bio, Celltrion, Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, Servier, Sandoz, MSD, TG Therapeutics, Takeda, Roche, Eusa Pharma, Kyowa Kirin, Novartis, ADC Therapeutics, Incyte and Beigene. N.K. reports honoraria from and a consulting or advisory role for Kite, a Gilead Company; and research funding from Neovii, Novartis and Riemser. A.L.-G. reports a consulting or advisory role for Celgene, Incyte, Kite, a Gilead company, Novartis, Roche and Takeda; research funding from Celgene, Kite and Roche; and travel, accommodation and expenses from Kite. H.G. and W.Z. have no relevant financial relationships to disclose. G.T. and F.M.M. report employment with Kite, a Gilead Company. J.B., C.T., M.S. and H.M. report employment with Kite, a Gilead Company; and stock or other ownership in Gilead Sciences. M.M. and P.C. report employment with Kite, a Gilead Company, and patents, royalties and other intellectual property, and travel support from Kite; and stock or other ownership with Gilead Sciences. A.B. reports former employment with Kite, a Gilead Company; current employment and a leadership role with Capstan Therapeutics; stock or other ownership with Capstan Therapeutics and Gilead Sciences; a consulting or advisory role for Cero Therapeutics and Elicio; and expert testimony for Gilead Sciences. R.S. reports employment with and stock or other ownership in Kite, a Gilead Company; and patents, royalties and other intellectual property from Atara and Kite. D.B. reports employment with Kite, a Gilead Company. J.G. reports employment with Veracyte; a leadership role and consulting or advisory role in Northwest Biotherapeutics and Lunaphore; stock or other ownership in and travel support from Veracyte; research funding from Imcheck Therapeutics and Veracyte; and patents, royalties or other intellectual property from Inserm.